Screening And Clinical Validation Of Differentially Expressed Genes In Prostate Tissues

purpose:1.Using bioinformatics methods to analyze prostate cancer and normal tissue gene expression profiles in public databases,and screen differentially expressed genes related to prostate cancer,laying the foundation for subsequent clinical research.2.Conduct a clinical study on the target gene TRIP13.The expression levels of TRIP 13 in prostate cancer,prostate cancer and benign prostatic hyperplasia were detected by PCR and immunohistochemistry.The mechanism of TRIP 13 development and progression in prostate cancer was studied,and the potential application value of TRIP13 in patients with prostate disease was evaluated.Method:1.Using the shared prostate cancer gene expression profile chip data obtained in the GEO database,using the limma,ggplot2,Hmisc and other tools in the R software for data mining,analyzing the differentially expressed genes,and screening through the bioinformatics tools DAVID,STRING.The genes were analyzed by GO and KEGG Pathway.2.Collecting tissue specimens of cancer,paracancerous and benign prostatic hyperplasia,and clinically relevant data for radical prostatectomy in the Second Affiliated Hospital of Kunming Medical University from June to February 2018,2017.The treatment was carried out according to the requirements of PCR and immunohistochemistry.The expression levels of TRIP 13 gene and protein in tissues were detected by RT-PCR and immunohistochemistry,and statistical analysis was performed with clinical data of patients.The correlation between TRIP 13 expression level and patient age,TNM stage,lymph node metastasis and gleason score was analyzed.To explore the role of TRIP 13 in the development of prostate cancer.Result:A total of 298 differentially expressed genes were screened by expression gene chip,of which 116 were up-regulated and 182 were down-regulated.A total of 52 genes were filtered using(logFC>2,P<0.05)to meet the requirements.A series of bioinformatics analysis of these genes screened 8 genes including KIF20A,DLGAP5,HMMR,TOP2A,MELK,TRIP13,TACC3 and CENPM.Combined with literature analysis,TRIP 13 may be a causative factor affecting the development of prostate cancer[1,2].RT-PCR results showed that the expression of TRIP 13 gene in prostate cancer and adjacent tissues was significantly higher than that in benign prostatic hyperplasia(P<0.05).There was no significant difference between cancer and adjacent tissues(P>0.05).There was no correlation between TRIP 13 gene expression level and patient age,PSA level,GLEASON score and TNM stage(p>0.05).The results of immunohistochemistry showed that the level of TRIP13 protein in prostate cancer was significantly higher than that in benign prostatic hyperplasia,which was consistent with the results of PCR.In conclusion:1.Eight genes were screened by expression gene chip for significant differential expression in prostate cancer.Among them,TRIP 13 may be a key gene affecting the development of prostate cancer.The mining of public databases can effectively obtain useful information on the pathogenic factors of the disease.The expression of TRIP 13 gene in prostate cancer tissues was significantly higher than that in hyperplasia and adjacent tissues.However,there was no correlation between TRIP 13 protein expression level and age,prostate specific antigen and TNM stage.The level of TRIP 13 protein in cancer tissues was significantly higher.In hyperplasia,it was further confirmed that TRIP 13 protein has a certain biological role in the development of prostate cancer,and provides experimental data support for the introduction of TRIP 13 protein into molecular targeted therapy of prostate cancer and as a potential diagnostic indicator.